Komori
ASKA Pharmaceutical Holdings (4886) · PolicyReframedLatest Share Issuance and Disposal (2026-07-13): "Advanced"

Executive Compensation System Incorporating Performance, Share-Based and ESG Metrics

First written in FY2024. 3 of 5 entries say "Advanced", first in 2026-05-25. Latest entry: 2026-07-13.

5entries
3years
3from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY20242024: 120242025: 020252026: 42026
Same theme, other companies
Compensation structure combining fixed, performance-based and stock-price-linked componentsA theme 447 companies write about · 1 as a headwind · 381 as a tailwind

87 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 448 threads.
Full recordFilings, disclosures and news, newest first
  1. 2026-07-13AdvancedShare Issuance and Disposal

    「As part of the review of the Company’s officer compensation system, we have decided to partially revise this system for directors other than directors serving as audit and supervisory committee members and outside directors, referred to below as “Eligible Directors 1,” in order to promote further value sharing with shareholders and provide incentives for the sustainable enhancement of corporate value. We have also decided to add outside directors, excluding directors serving as audit and supervisory committee members, as new eligible persons under the system, referred to below as “Eligible Directors 2,” to promote greater value sharing with shareholders and enable the management oversight function to contribute fully to enhancing corporate value.」

    The company specified the implementation of existing restricted stock compensation through an actual disposal of treasury shares, revisions to the service-based plan, introduction of performance-based restricted stock compensation and expansion of eligibility to outside directors, executive officers and officers and employees of subsidiaries.
  2. FY2026ReframedAnnual report

    「固定報酬、業績連動賞与、譲渡制限付株式報酬=50:20:30」

    監査等委員会設置会社への移行を前提に、取締役報酬の標準構成を固定報酬50%、業績連動賞与20%、譲渡制限付株式報酬30%へ変更する方針を記載している。社外取締役には固定報酬の10%を目安とする在籍条件型株式報酬を予定している。
  3. FY2024First statedAnnual report

    「取締役(社外取締役を除く)の報酬については、持続的な企業価値向上に資する報酬設計とし、具体的には、固定報酬のほかに短期インセンティブとなる業績連動賞与、中長期インセンティブとなる株式報酬制度で構成することといたします。」

    役員報酬について、固定報酬に加え、業績連動賞与、譲渡制限付株式報酬を組み合わせる制度を記載している。業績指標には営業利益、売上高、ROEおよびESG関連の非財務指標を用いている。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
ASKA Pharmaceutical Holdings's next results are scheduled for 2026-11-04. Read the earnings preview It last moved in the Share Issuance and Disposal of 2026-07-13: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.